Current Report Filing (8-k)
2022年4月13日 - 5:06AM
Edgar (US Regulatory)
0001468639
false
0001468639
2022-02-15
2022-02-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 15, 2022
Vicapsys
Life Sciences, Inc.
(Exact
name of registrant as specified in its charter)
Florida |
|
000-56145 |
|
91-1930691 |
(State
or other jurisdiction
of
incorporation or organization) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
7778
Mcginnis Ferry Rd. #270
Suwanee,
GA 30024
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (972) 891-8033
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
February 15, 2022, the Board of Directors (the “Board”) of Vicapsys Life Sciences, Inc. (the “Company”) appointed
Federico Pier as Chief Executive Officer of the Company. Mr. Pier has served as Interim Chief Executive Officer since August 2020, and
as Executive Chairman of the Board since May 2019.
Mr.
Pier, age 54, was appointed as the Executive Chairman of the Board in May 2019, and has served as the Company’s Interim Chief Executive
Officer since August 2020. He is the Managing Director of YPH, LLC, a multifamily office investing in life sciences, energy, and technology.
Mr. Pier has more than 25 years of experience in reverse mergers, structured finance, convertible debt and straight equity. He previously
as a Senior Director at Oppenheimer & Co. and Managing Director at Bear Stearns. He holds a Bachelors’ degree from the University
of North Texas and an MBA from the Graduate School of Management at the University of Dallas.
Item 8.01.
Other Events.
On April 12,
2022, the Company issued a press release regarding Mr. Pier’s appointment as Chief Executive Officer, a copy of which is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Vicapsys
Life Sciences, Inc |
|
|
Date:
April 12, 2022 |
/s/
Federico Pier |
|
Federico
Pier |
|
Chief
Executive Officer |
Vicapsys Life Sciences (CE) (USOTC:VICP)
過去 株価チャート
から 6 2024 まで 7 2024
Vicapsys Life Sciences (CE) (USOTC:VICP)
過去 株価チャート
から 7 2023 まで 7 2024